US FDA Approves New Parkinson’s Drug

For context, the US Food and Drug Administration has approved AbbVie's treatment for Parkinson's disease in adults.

Key points

• The drug, tavapadon, was acquired by AbbVie through its $8.7 billion purchase of Cerevel Therapeutics in 2023.
• Add ProPakistani to Preferred Sources and see more of our stories in Google Search and Top Stories.
• Add as a preferredSource on Google Follow on Google News Join WhatsApp.
• Juvmo is a once-a-day pill for patients with Parkinson's disease, a long-term brain disorder that gradually affects movement control and can cause tremors, stiffness and balance challenges.
• The FDA's approval was based on data from AbbVie's late-stage trial programme.

For context, the drug, tavapadon, was acquired by AbbVie through its $8.7 billion purchase of Cerevel Therapeutics in 2023. It will be sold under the brand name Juvmo.

AbbVie remarked more than 11 million residents worldwide live with the disease. Over 100 Life-Saving Medicines Face Shortage in Pakistan.

In practice, the drug works by mimicking dopamine, a vital brain chemical that naturally declines in individuals with Parkinson's disease.

Meanwhile, the FDA's approval was based on data from AbbVie's late-stage trial programme. It indicated the medicine improved symptoms in patients.

Common side effects documented in the trials included nausea, dizziness and headache.

AbbVie did not immediately comment on the drug's launch or pricing. Citi analysts had previously remarked the launch was anticipated in the third quarter of 2026, with uptake probable to be gradual as Medicare coverage negotiations continue. Stay Connected with ProPakistani. Obtain the latest international news and global stories wherever you prefer. Follow on Google Discover.

For now, US FDA Approves New Parkinson's Drug remains the part of the story worth watching, and further updates are likely as more details are confirmed.